Osimertinib could change the standard of care for EGFR-mutant NSCLC

Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X:

“Osimertinib could change the standard of care for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).

The LAURA trial showed that osimertinib improves progression-free survival (PFS) in patients with unresectable NSCLC, reducing the risk of progression or death by 84% vs. placebo.

The median PFS was 39.1 months vs. 5.6 months.

The most common adverse events were radiation pneumonitis, diarrhea, and rash.”

For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines

Source: Iván R. González/X